Comparison of Zotarolimus-Eluting Stent vs Sirolimus-Eluting Stent for Diabetic Patients

Inclusion Criteria: * Diabetic patients with angina and documented ischemia * Patients who are eligible for intracoronary stenting * De novo lesion * Percent diameter stenosis ≥50% * Reference vessel size ≥ 2.5 mm by visual estimation Exclusion Criteria: * History of bleeding diathesis or coagulopathy * Pregnant state * Known hypersensitivity or contra-indication to contrast agent and heparin * Limited life-expectancy (less than 1 year) * Acute ST elevation myocardial infarction on admission * Characteristics of lesion Left main disease In-stent restenosis Graft vessels * Hematological disease (Neutropenia \<3000/mm3, Thrombocytopenia \<100,000/mm3) * Hepatic dysfunction, liver enzyme (ALT and AST) elevation ≥ 3 times normal * Renal dysfunction, creatinine ≥ 2.0mg/dL * Contraindication to aspirin, clopidogrel or cilostazol * Left ventricular ejection fraction \<30% * Patients who are actively participating in another drug or device - investigational study, which have not completed the primary endpoint follow- up period. * Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment).